NCT04022993已完成3 期
An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of Insulin RinGlar® ("Geropharm", Russia) Compared to Lantus® SoloStar® ("Sanofi-Aventis Deutschland GmbH", Germany) in Type 1 Diabetes Mellitus Patients
Geropharm14 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2018年7月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 180
- 试验地点
- 14
- 主要终点
- Antibody Response
研究概览
简要总结
The study is designed to approve non-inferior efficacy and safety of Insulin RinGlar® compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written consent
- •Diabetes mellitus type 1 for at least 12 months prior to screening
- •History of basis-bolus (multiple dose injection (MDI)) therapy in stable doses at least 30 days
- •Glycated hemoglobin (HbA1c) level of 6.5 to 12.0 % at screening (both values inclusive)
- •Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive)
- •Subject is able and willing to comply with the requirements of the study protocol
排除标准
- •Contraindication to the use of Insulin glargine
- •Insulin resistance over 1.5 U/kg insulin pro day
- •History of treatment any biosimilar insulin
- •History of treatment any experimental drugs or medical devices for 3 months prior to screening
- •History of treatment insulin pump for 90 days prior to signed written consent or indication for use insulin pump
- •Presence of severe diabetes complications
- •History of severe hypoglycemia during 6 months prior to signed written consent
- •History of 15 or more episodes mild hypoglycemia during 1 month prior to signed written consent
- •History or presence of uncontrolled diabetes mellitus for 6 months prior to screening
- •History of administration of glucocorticoids for 1 year prior to screening
- •Administration of any immunosupressive drugs (Cyclosporinum, Methotrexatum, etc.)
- •History of autoimmune disease, except vitiligo and controlled autoimmune polyglandular syndrome (APS) types 1-3, except adrenal insufficiency
- •History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions
- •History of severe allergic reactions
- •Pregnant and breast-feeding women
- •Acute inflammation disease for 3 weeks prior to screening
- •Deviation of the laboratory results conducted during the screening:
- •Hemoglobin value < 9,0 g/dl; Hematocrit value < 30 %; ALT and AST value > 2 folds as high as maximal normal value; Serum bilirubin value > 1.5 folds as high as maximal normal value
- •History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, etc.)
- •Serious blood loss for 3 months prior to screening (blood donation, surgery procedure, etc.)
- •Incomplete recovery after surgery procedure
- •History of unstable angina, myocardial infarction, severe arrhythmia, heart failure III or IV NYHA for 1 year prior to screening
- •History of stroke or TIA for 6 months prior to screening
- •History of drug, alcohol abuse for 3 years prior to screening
- •Inability follow to protocol
- •History of oncological disease during 5 years prior to screening
- •Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg), hepatitis C (HCVAb) or syphilis (Treponema pallidum) antibodies at screening.
- •History of transplantation, except 3 months after corneal transplant
- •History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study
研究组 & 干预措施
Lantus® SoloStar®
Active Comparator
Lantus® SoloStar® once a day, individually glucose-level based administered in stable doses, started before enrollement
干预措施: Lantus Solostar, 100 Units/mL Subcutaneous Solution (Drug)
Insulin RinGlar®
Experimental
Insulin RinGlar® once a day, individually glucose-level based administered in stable doses, started before enrollement
干预措施: Insulin RinGlar, 100 Units/mL Subcutaneous Solution (Drug)
结局指标
主要结局
Antibody Response
时间窗: 26 weeks
Change from baseline in titer of antibodies to human insulin
次要结局
- Total Insulin Dose(26 weeks)
- Achievement of Glycated Hemoglobin Goals(26 weeks)
- Achievement of Glycated Hemoglobin < 7%(26 weeks)
- Basal Insulin Dose(26 weeks)
- Fasting Plasma Glucose Level(26 weeks)
- Seven-Point Glucose Testing(26 weeks)
- Body Mass Index(26 weeks)
- Adverse Events frequency and degree(26 weeks (4+22 weeks))
- Glycated hemoglobin(26 weeks)
- Treatment Satisfaction(26 weeks)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
3 期
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) PatientsType 1 Diabetes MellitusNCT02666430Mylan Inc.127
已完成
3 期
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT01683266Sanofi549
已完成
3 期
Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus PatientsDiabetes Mellitus, Type 2NCT04012775Geropharm201
已完成
4 期
A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes PatientsType2 DiabetesNCT02987751India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals200
已完成
3 期
Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus PatientsDiabetes MellitusDiabetes Mellitus, Type 2NCT04023344Geropharm210